JANX

Conviction 73HealthcareScan · Thu, Sep 24, 2026

Janux Therapeutics, Inc. (JANX) closed at $16.67 (+0.88%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 44, RS Rating 37, -52.0% from its 52-week high, +22.1% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

JANX$16.67+0.88%

ResistanceSupportVol 14Insider sell

Vol MA14 1.05M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Janux Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.januxrx.com ↗

Price16.67

Change+0.88%

Gap-0.97%

Rel volume1.80×

Avg volume1.04M

Avg $ vol18.64M

SMA 2017.95

SMA 5016.98

SMA 20014.96

Price vs 50-1.83%

Price vs 200+11.41%

MA stackmixed

50/200 cross—

Supertrenddown · 18.67

RSI (14)44

MACD hist-0.24

MACD cross—

Stoch %K / %D19 / 21

ADX (14)22

+DI / −DI21 / 33

RSI divergence—

MACD divergenceBearish

ATR %4.67%

ADR %4.38%

52w high34.74

52w low12.18

From 52w high-52.03%

Above 52w low+36.82%

New 52w highNo

SqueezeOff

Bollinger width29.02%

%B0.25

Donchian pos19.45%

Donchian high20.31

Donchian low15.79

AVWAP (52w high)15.39

vs AVWAP high+8.27%

AVWAP (52w low)15.08

vs AVWAP low+10.53%

OBV trendFlat

Chaikin MF (20)0.03

Today vs 20d1.80×

Avg vol (14d)1.05M

Avg vol (20d)1.04M

Avg $ vol (20d)18.64M

Market cap1.02B

RS Rating37 / 99

RS 3m (vs SPY)+9.81%

RS 6m (vs SPY)+3.94%

RS line new highNo

Trend template5/8

Technical rank64.5

1 week-1.16%

1 month-10.79%

3 months+14.30%

6 months+20.76%

1 year-27.48%

YTD+22.09%

P/E-8.97

P/B1.10

P/S101.88

P/FCF-12.23

EPS-1.83

Div yield—

ROE-12.24%

ROA-11.28%

Debt/Eq—

Current16.35

EV/EBITDA—

Gross margin—

Net margin—

Rev growth-5.55%

EPS growth-64.69%

Price target34.22

Target upside105.34%

Analyst ratingBuy

Institutional111.74%

Ent. value991.08M

Revenue10.27M

Net income-21.97M

Gross profit—

Free cash flow-83.28M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out60.98M

Employees108

ListedFri, Jun 11, 2021

Free float37.06M

Float %61.6%

Short interest6.06M

Days to cover7.8d

Short volume48.6%

Squeeze score75 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.35 vs −$0.26

Last surprise-34.6% miss

Setup gradeB

Conviction73 / 100

Pattern quality—

Tech rank64.5 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance19.73

Support15.72

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in JANX

All disclosures →

No recent disclosed trades by Congress in JANX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in JANX · open-market 2 sells

Insider	Side	Shares	Value	Traded	Filed
Campbell David Alan President and CEO · Common Stock · 2026-07-08	Exercise	7K	$29K	2026-07-08	2026-07-10
Campbell David Alan President and CEO · Stock Option (right to buy) · 2026-07-08	Exercise	7K	—	2026-07-08	2026-07-10
Barrett Ronald W Director · Common Stock · 2026-06-11	Grant	5.5K	—	2026-06-11	2026-06-12
Barrett Ronald W Director · Stock Option (right to buy) · 2026-06-11	Grant	15.5K	—	2026-06-11	2026-06-12
Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr · Common Stock · 2026-06-02	Sell	4.06K	$57K	2026-06-02	2026-06-04
Dobek Maria Vice President, Accounting · Common Stock · 2026-05-11	Sell	2.04K	$29K	2026-05-11	2026-05-13

SEC filings

EDGAR filings in JANX · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.